These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400 [TBL] [Abstract][Full Text] [Related]
14. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734 [TBL] [Abstract][Full Text] [Related]
15. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689 [TBL] [Abstract][Full Text] [Related]
16. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Madden SF; Clarke C; Gaule P; Aherne ST; O'Donovan N; Clynes M; Crown J; Gallagher WM Breast Cancer Res; 2013; 15(4):R52. PubMed ID: 23820017 [TBL] [Abstract][Full Text] [Related]
17. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465 [TBL] [Abstract][Full Text] [Related]
18. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer. Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157 [TBL] [Abstract][Full Text] [Related]
19. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611 [TBL] [Abstract][Full Text] [Related]